CovidSurg-Cancer is an international, multicentre, observational cohort study designed to
evaluate the 30-day COVID-19 infection rates in elective cancer surgery during the
COVID-19 pandemic.
Centres can elect to include one or more cancer types in the study, in any combination,
depending on local expertise and capacity. During the pilot study, investigators should
enrol patients with confirmed diagnoses of:
- Colorectal cancer
- Oesophagogastric cancer
As a rapid response study to the COVID-19 pandemic, included cancer types will evolve
throughout the course of the CovidSurg-Cancer study period, for example, to include
breast, liver, pancreatic, gynaecological, urological cancers, or sarcomas.
Additional locations may be listed on ClinicalTrials.gov for NCT04384926.
See trial information on ClinicalTrials.gov for a list of participating sites.
The rapid emergence of the COVID-19 virus has led to a global impact on elective surgical
care.
We have very little evidence to guide us. The magnitude and effects of these changes are
uncertain. The safety of operating on patients electively with the risks of COVID-19
postoperative pneumonia is unknown.
High-quality data will allow policy planning at regional and hospital level for both this
outbreak and future pandemics. CovidSurg-Cancer will run in parallel to CovidSurg (which
is capturing outcomes of patients undergoing surgery for all indications with concurrent
COVID-19).
The primary aim is to evaluate the 30-day COVID-19 infection rates in elective cancer
surgery during the COVID-19 pandemic.
Secondary aims include; comparison of the 30-day postoperative mortality rate in cancer
surgery patients that develop COVID-19 infection versus those who do not; an exploration
of the scale of resource constraints related to the COVID-19 pandemic, and their impact
on outcomes of elective cancer surgery; to explore variation in the selection of patients
for continuing elective cancer surgery during the COVID-19 pandemic; to evaluate the
impact of the COVID-19 pandemic on treatment pathways for cancers with a decision for
surgical resection with curative intent.
This investigator-led, non-commercial, non-interventional study is extremely low to zero
risk. This study does not collect any patient identifiable information and data will not
be analysed at hospital-level.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationUniversity of Birmingham
